Senti Biosciences, Inc. cash flow to debt ratio of -150.37% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Senti Biosciences, Inc.'s free cash flow has decreased 5.35% from $-41.42M last year to $-43.64M, signaling decreasing performance

Senti Biosciences, Inc.'s debt to equity ratio is 7.46, which means that the company's assets are unhealthy financed, signaling financial risk.

Senti Biosciences, Inc.'s debt has increased relative to shareholder equity from 1.31 last year to 7.46 today, signaling weakened financials

Senti Biosciences, Inc. has negative EBITDA, making leverage ratio unreliable

Senti Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Senti Biosciences, Inc. has insufficient data to evaluate this check.

Senti Biosciences, Inc.'s short-term assets of $23.27M exceed its short-term liabilities of $13.97M

Senti Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Senti Biosciences, Inc.'s return on equity of -503.79%, is lower than 15.00%, indicating bad performance

Senti Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Senti Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Senti Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Senti Biosciences, Inc. has negative free cash flow, indicating cash burn

Senti Biosciences, Inc.'s yearly earnings has decreased 16.38% since last year from $-52.79M to $-61.44M, signaling decreasing performance

Senti Biosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -196.99% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Senti Biosciences, Inc.'s 3-year revenue CAGR of -81.15% is negative, indicating declining revenue over the past 3 years

Senti Biosciences, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Senti Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Senti Biosciences, Inc. has insufficient data to evaluate this check.

Senti Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Senti Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Senti Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Senti Biosciences, Inc. has insufficient data to evaluate this check.

Senti Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Senti Biosciences, Inc. has a price-to-book ratio of 4.21x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Senti Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue